Denali Therapeutics (DNLI) Depreciation & Amortization (CF) (2017 - 2026)

Denali Therapeutics (DNLI) has reported Depreciation & Amortization (CF) for 10 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 22.37% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $11.7 million (up 47.06% YoY), while the FY2025 annual figure was $11.2 million, up 43.46% from the prior year.
• Depreciation & Amortization (CF) declined to $2.8 million in Q1 2026 per DNLI's latest filing, from $2.9 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $10.0 million in Q1 2023 and bottomed at $1.8 million in Q3 2024.
• Historically, Depreciation & Amortization (CF) has averaged $2.9 million across 5 years, with a median of $2.2 million in 2023.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) jumped 383.26% — and 2024, when it slumped 78.48%.
• Denali Therapeutics' Depreciation & Amortization (CF) stood at $4.1 million in 2022, then plunged by 47.01% to $2.2 million in 2023, then decreased by 14.88% to $1.9 million in 2024, then jumped by 54.67% to $2.9 million in 2025, then declined by 0.73% to $2.8 million in 2026.
• Business Quant data shows DNLI's Depreciation & Amortization (CF) at $2.8 million in Q1 2026, $2.9 million in Q4 2025, and $2.9 million in Q3 2025.